Clinicopathological features for epithelioid glioblastoma:A newly defined tumor by the 2016 World Health Organization Classification of Tumors of the Central Nervous System
10.11817/j.issn.1672-7347.2018.04.010
- VernacularTitle:WHO(2016)中枢神经系统肿瘤新增分类上皮样胶质母细胞瘤的临床病理特征
- Author:
Juan LI
1
;
Xuebing LING
;
Mingyao LAI
;
Qingjun HU
;
Changguo SHAN
;
Linbo CAI
Author Information
1. 广东三九脑科医院肿瘤科
- Keywords:
epithelioid glioblastoma;
clinicopathological features;
treatment;
prognosis
- From:
Journal of Central South University(Medical Sciences)
2018;43(4):398-402
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To retrospectively summarize the clinicopathological features of epithelioid glioblastoma (Ep-GBM) and to explore new treatment for Ep-GBM.Methods:The clinical data of 13 patients with Ep-GBM,who were treated in our department from March 2016 to July 2017,were retrospectively analyzed.The clinicopathological features were summarized and the efficacy was evaluated.Results:The positive rate of BRAFV600E mutant and INI-1 was 76.9％ (10/13) and 80％ (8/10),respectively,while the median Ki-67 index was 30％.Meningeal metastases occurred in 9 cases (69.7％) during the course.The median follow-up time was 12 (6-25) months,and the median progression-free time was 8.6 (2.2-16.5) months.Three patients died and the 1-year overall survival rate was 54％.Conclusion:Ep-GBM has a high degree of malignancy and is prone to spread to leptomeninges.INI-1 expression and BRAFV600E mutation are common for Ep-GBM.BRAF inhibitor might be a potential therapeutic drug for it.
